Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Waldenstrom Macroglobulinemia 1Solid Tumors 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1

Interventions

Pemetrexed 40Cisplatin 35pembrolizumab 21Nivolumab 17Carboplatin 16Ipilimumab 13Gemcitabine 10Cyclophosphamide 9fludarabine 6durvalumab 6Bevacizumab 6Radiotherapy, Intensity-Modulated 4LMB-100 4Drug Therapy 4Dexamethasone 4tremelimumab 3tazemetostat 3spartalizumab 3olaparib 3niraparib 3atezolizumab 3anetumab ravtansine 3amatuximab 3Vinorelbine 3Paclitaxel 3Oxaliplatin 3Imatinib Mesylate 3Fluorouracil 3Cerebral Decortication 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × CB-839 × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡